Apparent Life-Threatening Events (ALTE) in infants often lead to severe neurological complications or to sudden death. In such situations, cardio-pediatricians and intensive care physicians have no specific diagnosis or treatment. In a recent translational research (INSERM-DHOS), our team has reported a myocardiac abnormality in a rabbit model of vagal hyperreactivity which is also present in the human hearts of infants deceased from sudden death, i.e. increased M2 muscarinic receptors (M2R) density associated with compensative increased enzymatic activity and overexpression of acetylcholine esterase (AchE). In a recent PHRC-I study (article in preparation), these abnormalities have also been observed in the blood of patients, infants as well as adults, exhibiting severe vagal syncopes. We observed, even more importantly, similar abnormalities in infants under 1 year of age with very severe idiopathic ALTE (iALTE) compared with normal subjects and with patients who presented ALTE with identified etiologies (JAMA Pediatric, 2016 May). The aim of this present study is to validate the overexpression of M2R as a marker of risk of iALTE in infant under 1 year.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Enrollment
30
Standard management of ALTE * Hospitalization in pediatric intensive care unit or pediatric emergencies * Etiologic research * Blood volume, 2.5mL in PaxGene® tube, for specific analyzes (M2R, AchE)
Pediatric Intensive Care unit/Emergency unit - Besançon University Hospital
Besançon, France
NOT_YET_RECRUITINGPediatric Intensive Care Unit - Brabois Hospital - Nancy University Hospital
Nancy, France
RECRUITINGPediatric unit - Maison Blanche Hospital - Reims University Hospital
Reims, France
RECRUITINGPediatric intensive care unit/ Pediatric unit- Strasbourg University Hospital - Hautepierre Hospital
Strasbourg, France
RECRUITINGMuscarinic M2 receptor mRNA expression in blood
Blood sample will be collected not later than 24 hours after the inclusion in the study and will be frozen until centralized analysis. A qRT-PCR will be performed for quantification of CHRM2 gene expression in blood (mRNA expression). Interim analysis with the 7-8 first samples per group together. Final analysis with all samples at the study completion.
Time frame: At the admission in the hospital, within 24 hours after the inclusion in the study
Acetylcholinesterase mRNA expression in blood
Blood sample will be collected not later than 24 hours after the inclusion in the study and will be frozen until centralized analysis.. A qRT-PCR will be performed for quantification of ACHE gene expression in blood (mRNA expression). Interim analysis with the 7-8 first samples per group together. Final analysis with all samples at the study completion.
Time frame: At the admission in the hospital, within 24 hours after the inclusion in the study.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.